Cidara Therapeutics (NASDAQ:CDTX) added ~15% on Wednesday after the biotech announced an accelerated timeline for a Phase 3 registrational trial designed to evaluate its experimental flu therapy CD388. The update followed an End-of-Phase 2 meeting the company conducted with the ...